IceCure Medical (NASDAQ:ICCM) Stock Rating Upgraded by Wall Street Zen

IceCure Medical (NASDAQ:ICCM) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $2.64.

IceCure Medical Price Performance

Shares of IceCure Medical stock opened at $0.59 on Friday. The firm has a 50 day simple moving average of $0.66 and a 200 day simple moving average of $0.81. IceCure Medical has a fifty-two week low of $0.54 and a fifty-two week high of $1.66. The firm has a market cap of $40.53 million, a P/E ratio of -2.27 and a beta of 0.29.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, November 19th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.85 million during the quarter, compared to the consensus estimate of $0.63 million. IceCure Medical had a negative net margin of 513.95% and a negative return on equity of 243.68%. On average, sell-side analysts expect that IceCure Medical will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Concurrent Investment Advisors LLC bought a new stake in IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 78,285 shares of the company’s stock, valued at approximately $48,000. Concurrent Investment Advisors LLC owned approximately 0.11% of IceCure Medical as of its most recent filing with the Securities and Exchange Commission (SEC). 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.